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 Abstract 
Background: A core outcome set (COS; an agreed, minimum set of outcomes) was needed to address the heterogeneous measurement of 
outcomes in aphasia treatment research and to facilitate the production of transparent, meaningful and efficient outcome data.  
Objective: The Research Outcome Measurement in Aphasia (ROMA) consensus statement provides evidence-based recommendations for the 
measurement of outcomes for adults with post-stroke aphasia within phase I-IV aphasia treatment studies. 
Methods: This statement was informed by a four-year program of research which comprised investigation of stakeholder-important outcomes 
using consensus processes, a scoping review of aphasia outcome measurement instruments, and an international consensus meeting.  This paper 
provides an overview of this process and presents the results and recommendations arising from the international consensus meeting.  
Results: Five essential outcome constructs were identified: Language, communication, patient-reported satisfaction with treatment and impact of 
treatment, emotional wellbeing, and quality of life. Consensus was reached for the following measurement instruments: Language: The Western 
Aphasia Battery Revised (WAB-R) (74% consensus); emotional well-being: General Health Questionnaire (GHQ)-12 (83% consensus); quality 
of life: Stroke and Aphasia Quality of Life Scale (SAQOL-39) (96% consensus). Consensus was unable to be reached for measures of 
communication (where multiple measures exist) or patient-reported satisfaction with treatment or impact of treatment (where no measures exist).   
Discussion: Harmonisation of the ROMA COS with other core outcome initiatives in stroke rehabilitation is discussed.  Ongoing research and 
consensus processes are outlined.  
Conclusion: The WAB-R, GHQ, and SAQOL-39 are recommended to be routinely included within phase I-IV aphasia treatment studies. This 
consensus statement has been endorsed by the Collaboration of Aphasia Trialists, the British Aphasiology Society, the German Society for 
Aphasia Research and Therapy, and the Royal College of Speech Language Therapists. 
 
A core outcome set for aphasia treatment research: the ROMA consensus statement 
The Research Outcome Measurement in Aphasia (ROMA) consensus statement provides recommendations for a core outcome set (COS) for use 
in aphasia treatment studies. A COS is a minimum set of outcomes that should be measured and reported in research trials of a specific health 
condition or population (1). The use of a COS does not preclude the measurement of additional outcomes, but rather represents the minimum 
outcomes that should be collected and reported (2). A COS for aphasia was developed in response to a trend of heterogeneous outcome 
measurement in research and the merits of this initiative were debated in a published forum in 2014 (3-7). The ROMA consensus statement was 
informed by a four-year program of research in three phases: (1) investigation of stakeholder-important outcomes using consensus processes (8-
11); (2) a scoping review to identify aphasia outcome measurement instruments (OMIs) and their psychometric properties (12); and (3) an 
international consensus meeting (results reported herein). The ROMA COS is intended to complement other existing and ongoing initiatives to 
standardise the measurement of stroke recovery (13-15).  
Objective  
The ROMA consensus statement provides evidence-based recommendations for the measurement of outcomes for adults with post-stroke 
aphasia within phase I-IV aphasia treatment studies. 
Target users 
The primary users of this consensus statement will be researchers involved in the design and conduct of aphasia treatment studies. 
 
Methods 
The research methods are based on the recommendations of the Core Outcome Measures in Effectiveness Trials (COMET) Initiative (2, 16) and 
are reported in alignment with the COS-STAR (Core Outcome Set-STAndards for Reporting) statement (17). The World Health Organization 
International Classification of Functioning, Disability and Health (ICF) (18) has been used as a conceptual framework and classification tool. 
This project is registered with the COMET Initiative (http://www.comet-initiative.org/studies/details/287).  
Stage 1: Identification of Core Outcome Constructs 
Outcome constructs were derived from three separate stakeholder consensus studies conducted with: people with aphasia and their families (9); 
aphasia clinicians and managers (8); and aphasia researchers (10).  Outcomes prioritised by stakeholder groups were integrated using the 
framework of the ICF (19). Essential constructs were identified as: Language, communication, patient-reported satisfaction with treatment and 
impact of treatment, emotional wellbeing, and quality of life (11). 
Stage 2: Identification of Outcome Measurement Instruments 
A scoping review was conducted to identify OMIs which have been validated with people with aphasia. Primary searches were run using 
PUBMED, EMBASE, and CINAHL databases on 10 November 2015. The search strategy incorporated filters developed for the identification of 
studies reporting the measurement properties of health OMIs (see 20 and supplementary file). Inclusion criteria required that studies focused on 
the psychometric properties of measurement instrument and included participants with aphasia or stroke patients where participants with aphasia 
were not specifically excluded. Studies reporting measurement instruments which primarily measure neurological function associated with, but 
not central to aphasia: e.g., consciousness; health; motor speech; cognition; memory; were excluded. Secondary searches were conducted for 
each OMI identified in the first search. In total, 184 references for 79 measurement instruments were identified (12). No measures of patient-
reported treatment impact or patient-reported satisfaction were identified through this search.  
Stage 3. Formation of Consensus Panel  
Researchers who participated in the first phase of this project (n=80) (10) were invited to participate in the final consensus meeting. These 
researchers were purposively sampled from researchers whose trials were included with the Cochrane Collaboration review of "Speech and 
language therapy for aphasia following stroke"(21) and the 100 most highly published aphasia treatment researchers in the Web of Science 
database. In total, 23 researchers participated in a consensus meeting in London, UK (December, 2016).  Panel members were experienced 
researchers with expertise in: the design and conduct of aphasia trials; measurement instrument development and testing; and clinical guidelines 
development (see table 1 and supplementary table 1). Authors Wallace, Worrall, Le Dorze and T. Rose facilitated the COS development process 
and did not participate in COS voting. 
Table 1 
Characteristics of researchers who participated in the international consensus panel (n=23) 
Panel Characteristics n (%) 
Country  
    United Kingdom 9 (39) 
    United States of America 6 (26) 
    Australia 3 (13) 
    Canada 2 (9) 
    Germany 1 (4) 
    Sweden 1 (4) 
    Ireland 1 (4) 
ICF component to which their own research relates (panel 
members could nominate more than one component) 
 
   Body functions 16 
   Activity/Participation 21 
   Environmental factors 10 
   Personal factors 15 
   Quality of life* 12 
Number of treatment studies published by participants  
   1 2 
   2-5 8 
   6-10 4 
   more than 10 7 
   not specified 2 
*nb. Quality of life is not defined as a component of the ICF 
 Stage 4. International Consensus Meeting 
Ethical approval for the consensus meeting was gained from the Behavioural and Social Sciences Ethical Review Committee at The University 
of Queensland, Australia. The following process was used:  
Prior to meeting 
(1) Panel members generated consensus-based criteria to enable an initial reduction of OMIs (see table 2).  
(2) The consensus-based criteria were applied to the list of OMIs identified in the stage 2 scoping review (n=79) to produce a short-list (n=50) 
(see supplementary table 2).   
(3) Panel members generated consensus-based feasibility criteria (see table 3). 
(4) The short-listed OMIs (see supplementary table 2) were assigned to panel members, who reviewed OMI feasibility and measurement 
properties prior to the consensus meeting.   
 
 
During the meeting 
(1) Panel members engaged in a whole-group discussion using an iterative process to apply feasibility criteria and eliminate OMIs.  
(2) Panel members divided to smaller groups to review the measurement properties for each OMI in the target population (people with aphasia). 
Properties considered included: acceptability/feasibility of use with people with aphasia, reliability (test-retest, inter- and intra- as 
applicable), construct validity, and sensitivity to change.  
(3) Each small group recommended two OMIs for voting. Panel members voted YES/NO for each OMI in a closed voting process with 
consensus defined a priori as agreement on each OMI for each outcome construct by ≥ 70% of meeting participants, as suggested by the 
COMET initiative and GRADE working group (2). Potential conflicts of interest were managed through agreement that authors of OMIs 
under consideration could not participate in voting for that construct area.   
Table 2 
Criteria for initial reduction of outcome measurement instruments 
Measures were excluded if: 
1. The purpose of the measurement instrument was to screen for the presence of aphasia, 
rather than to measure outcomes. 
2. The measurement instrument was published more than thirty years ago (i.e., prior to 
1986) without subsequent revision and/or was not in current use. 
3. The measurement instrument targeted only one severity level of aphasia.  
4. For measures of language: the measurement instrument did not assess all modalities of 
language (e.g. reading only, writing only, comprehension only, verbal output only).  
  
 
Table 3 
Feasibility criteria  
1. Availability in different languages or ease of translation/adaptation. 
2. Cost. 
3. Burden to respondents or researchers (ease of administration, length of outcome 
measurement instrument, completion time). 
4. Ease of score calculation and provision of an aggregate score. 
 
 
Results  
After compilation of votes, panel members reached consensus for measures of language, emotional wellbeing, and quality of life (refer to table 
4). A consensus of ≥ 70% was not reached for a measure of communication.  Inability to gain consensus on a measure of communication may 
relate to the multi-factorial nature of this construct, as well a lack of understanding and consensus around how ‘effective communication’ is best 
operationalised in treatment research.  
 
Table 4 
Results of final voting to decide core outcome measurement instruments 
Construct Measure* Votes for 
inclusion 
Language The Western Aphasia Battery Revised (WAB-R)  74% (n=17) 
 The Comprehensive Aphasia Test (CAT) 22% (n=5) 
 Neither 4% (n=1) 
Communication The Scenario Test 57% (n=13) 
 The Communication Effectiveness Index (CETI) 39% (n=9) 
 Abstained 4% (n=1) 
Emotional well-
being 
General Health Questionnaire (GHQ)-12  83% (n=19) 
 Stroke Aphasic Depression Questionnaire (SADQ) 17% (n=4) 
Quality of life Stroke and Aphasia Quality of Life Scale (SAQOL-
39)  
96% (n=22) 
 Burden of Stroke Scale (BOSS) 0% (n=0) 
 Abstained 4% (n=1) 
Bolded figures indicate consensus criteria (≥70%) reached and OMI included in COS 
*Refer to supplementary tables 3 & 4 for OMI characteristics, properties and references. 
 
Recommendations 
It is recommended that the WAB-R, GHQ-12 and SAQOL-39 be included as core outcome measurement instruments in phase I-IV aphasia 
treatment studies for adults with post-stroke aphasia. These outcome measurement instruments and their psychometric properties are described in 
supplementary tables 3 & 4.  
 
Discussion 
The importance of implementing standardised approaches to outcome measurement in research trials is increasing acknowledged. In the field of 
stroke rehabilitation, the Stroke Recovery and Rehabilitation Roundtable (SRRR) (13) have provided consensus-based core recommendations for 
the measurement of sensorimotor recovery after stroke. Other initiatives have addressed the measurement of stroke outcomes in clinical practice 
(15) and there are ongoing works to standardise measures in arm rehabilitation trials after stroke (14). The ROMA COS has sought to provide 
recommendations specifically for the measurement of aphasia recovery post-stroke. Accordingly, some frequently used measures of global 
disability and health-related quality of life (e.g., EQ-5D) which do not contain communication-specific items or which have not been validated 
with stroke survivors with aphasia were not considered within this process. The ROMA COS seeks to harmonise with other existing stroke 
rehabilitation initiatives in addressing the need for standardised approaches to research trial outcomes measurement and its supplementary use 
may therefore be considered in any stroke study where people with aphasia are included.   
 
Future Directions 
The ROMA COS will be reviewed biennially. The next consensus meeting will focus on measures of communication and consider the 
development of measures of patient-reported satisfaction with treatment / impact of treatment. Factors relating to international COS 
implementation will be considered. New publications, initiatives and user feedback will also be considered in each review to: align this COS 
with other COSs; consider new OMIs; and to review the choice of OMIs based on user feedback. 
 
Limitations 
Participants in the international consensus meeting were predominately from English speaking countries. This may have impacted the consensus 
process and findings. Future meetings will seek to increase the diversity of participants with respect to cultural and linguistic background.  
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Supplemental File Search Strategy 
 
Search strategy (incorporates filters developed by Terwee and associates for the identification of studies reporting the measurement properties of 
health outcome measures; see Terwee CB, Jansma EP, Riphagen I, Vet HW. Development of a methodological PubMed search filter for finding 
studies on measurement properties of measurement instruments. Quality of Life Research 2009;18(8):1115-23.) 
 
PUBMED 
Aphasia OR dysphasia AND stroke 
AND 
(instrumentation[sh] OR methods[sh] OR Validation Studies[pt] OR Comparative Study[pt] OR ‘‘psychometrics’’ [MeSH] OR psychometr*[tiab] OR 
clinimetr*[tw] OR clinometr*[tw] OR ‘‘outcome assessment (health care)’’[MeSH] OR outcome assessment[tiab] OR outcome measure*[tw] OR Qual Life 
Res (2009) 18:1115–1123 1121 123 ‘‘observer variation’’[MeSH] OR observer variation[tiab] OR ‘‘Health Status Indicators’’[Mesh] OR ‘‘reproducibility of 
results’’[MeSH] OR reproducib*[tiab] OR ‘‘discriminant analysis’’[MeSH] OR reliab*[tiab] OR unreliab*[tiab] OR valid*[tiab] OR coefficient[tiab] OR 
homogeneity[tiab] OR homogeneous[tiab] OR ‘‘internal consistency’’[tiab] OR (cronbach*[tiab] AND (alpha[tiab] OR alphas[tiab])) OR (item[tiab] AND 
(correlation*[tiab] OR selection*[tiab] OR reduction*[tiab])) OR agreement[tiab] OR precision[tiab] OR imprecision[tiab] OR ‘‘precise values’’[tiab] OR 
test– retest[tiab] OR (test[tiab] AND retest[tiab]) OR (reliab* [tiab] AND (test[tiab] OR retest[tiab])) OR stability[tiab] OR interrater[tiab] OR inter-
rater[tiab] OR intrarater[tiab] OR intra-rater[tiab] OR intertester[tiab] OR inter-tester[tiab] OR intratester[tiab] OR intra-tester[tiab] OR interobserver[tiab] 
OR inter-observer[tiab] OR intraobserver[tiab] OR intraobserver[tiab] OR intertechnician[tiab] OR inter-technician[tiab] OR intratechnician[tiab] OR intra-
technician[tiab] OR interexaminer[tiab] OR inter-examiner[tiab] OR intraexaminer[tiab] OR intra-examiner[tiab] OR interassay[tiab] OR inter-assay[tiab] 
OR intraassay[tiab] OR intra-assay[tiab] OR interindividual[tiab] OR inter-individual[tiab] OR intraindividual[tiab] OR intra-individual[tiab] OR 
interparticipant [tiab] OR inter-participant[tiab] OR intraparticipant[tiab] OR intra-participant[tiab] OR kappa[tiab] OR kappa’s[tiab] OR kappas[tiab] OR 
repeatab*[tiab] OR ((replicab*[tiab] OR repeated[tiab]) AND (measure[tiab] OR measures[tiab] OR findings[tiab] OR result[tiab] OR results[tiab] OR test[- 
tiab] OR tests[tiab])) OR generaliza*[tiab] OR generalisa*[tiab] OR concordance[tiab] OR (intraclass[tiab] AND correlation*[tiab]) OR discriminative[tiab] 
OR ‘‘known group’’[tiab] OR factor analysis[tiab] OR factor analyses[tiab] OR dimension*[tiab] OR subscale*[tiab] OR (multitrait[tiab] AND scaling[tiab] 
AND (analysis[tiab] OR analyses[tiab])) OR item discriminant[tiab] OR interscale correlation*[tiab] OR error[tiab] OR errors[tiab] OR ‘‘individual 
variability’’[tiab] OR (variability[tiab] AND (analysis[tiab] OR values[tiab])) OR (uncertainty[tiab] AND (measurement[tiab] OR measuring[tiab])) OR 
‘‘standard error of measurement’’[tiab] OR sensitiv*[tiab] OR responsive*[tiab] OR ((minimal[tiab] OR minimally[tiab] OR clinical[tiab] OR 
clinically[tiab]) AND (important[tiab] OR significant[tiab] OR detectable[tiab]) AND (change[tiab] OR difference[tiab])) OR (small*[tiab] AND (real[tiab] 
OR detectable[tiab]) AND (change[tiab] OR difference[tiab])) OR meaningful change [tiab] OR ‘‘ceiling effect’’[tiab] OR ‘‘floor effect’’[tiab] OR ‘‘Item 
response model’’[tiab] OR IRT[tiab] OR Rasch[tiab] OR ‘‘Differential item functioning’’[tiab] OR DIF[tiab] OR ‘‘computer adaptive testing’’[tiab] OR 
‘‘item bank’’[tiab] OR ‘‘cross-cultural equivalence’’[tiab]) 
 
EMBASE 
aphasia OR dysphasia AND stroke 
AND 
'intermethod comparison'/exp OR 'data collection method'/exp OR 'validation study'/exp OR 'feasibility study'/exp OR 'pilot study'/exp OR 'psychometry'/exp 
OR 'reproducibility'/exp OR reproducib*:ab,ti OR 'audit':ab,ti OR psychometr*:ab,ti OR clinimetr*:ab,ti OR clinometr*:ab,ti OR 'observer variation'/exp OR 
'observer variation':ab,ti OR 'discriminant analysis'/exp OR 'validity'/exp OR reliab*:ab,ti OR valid*:ab,ti OR 'coefficient':ab,ti OR 'internal consistency':ab,ti 
OR (cronbach*:ab,ti AND ('alpha':ab,ti OR 'alphas':ab,ti)) OR 'item correlation':ab,ti OR 'item correlations':ab,ti OR 'item selection':ab,ti OR 'item 
selections':ab,ti OR 'item reduction':ab,ti OR 'item reductions':ab,ti OR 'agreement':ab,ti OR 'precision':ab,ti OR 'imprecision':ab,ti OR 'precise values':ab,ti 
OR 'test-retest':ab,ti OR ('test':ab,ti AND 'retest':ab,ti) OR (reliab*:ab,ti AND ('test':ab,ti OR 'retest':ab,ti)) OR 'stability':ab,ti OR 'interrater':ab,ti OR 'inter-
rater':ab,ti OR 'intrarater':ab,ti OR 'intra-rater':ab,ti OR 'intertester':ab,ti OR 'inter-tester':ab,ti OR 'intratester':ab,ti OR 'intratester':ab,ti OR 
'interobeserver':ab,ti OR 'inter-observer':ab,ti OR 'intraobserver':ab,ti OR 'intraobserver':ab,ti OR 'intertechnician':ab,ti OR 'inter-technician':ab,ti OR 
'intratechnician':ab,ti OR 'intratechnician':ab,ti OR 'interexaminer':ab,ti OR 'inter-examiner':ab,ti OR 'intraexaminer':ab,ti OR 'intraexaminer':ab,ti OR 
'interassay':ab,ti OR 'inter-assay':ab,ti OR 'intraassay':ab,ti OR 'intra-assay':ab,ti OR 'interindividual':ab,ti OR 'inter-individual':ab,ti OR 'intraindividual':ab,ti 
OR 'intra-individual':ab,ti OR 'interparticipant':ab,ti OR 'inter-participant':ab,ti OR 'intraparticipant':ab,ti OR 'intraparticipant':ab,ti OR 'kappa':ab,ti OR 
'kappas':ab,ti OR 'coefficient of variation':ab,ti OR repeatab*:ab,ti OR (replicab*:ab,ti OR 'repeated':ab,ti AND ('measure':ab,ti OR 'measures':ab,ti OR 
'findings':ab,ti OR 'result':ab,ti OR 'results':ab,ti OR 'test':ab,ti OR 'tests':ab,ti)) OR generaliza*:ab,ti OR generalisa*:ab,ti OR 'concordance':ab,ti OR 
('intraclass':ab,ti AND correlation*:ab,ti) OR 'discriminative':ab,ti OR 'known group':ab,ti OR 'factor analysis':ab,ti OR 'factor analyses':ab,ti OR 'factor 
structure':ab,ti OR 'factor structures':ab,ti OR 'dimensionality':ab,ti OR subscale*:ab,ti OR 'multitrait scaling analysis':ab,ti OR 'multitrait scaling 
analyses':ab,ti OR 'item discriminant':ab,ti OR 'interscale correlation':ab,ti OR 'interscale correlations':ab,ti OR ('error':ab,ti OR 'errors':ab,ti AND 
(measure*:ab,ti OR correlat*:ab,ti OR evaluat*:ab,ti OR 'accuracy':ab,ti OR 'accurate':ab,ti OR 'precision':ab,ti OR 'mean':ab,ti)) OR 'individual 
variability':ab,ti OR 'interval variability':ab,ti OR 'rate variability':ab,ti OR 'variability analysis':ab,ti OR ('uncertainty':ab,ti AND ('measurement':ab,ti OR 
'measuring':ab,ti)) OR 'standard error of measurement':ab,ti OR sensitiv*:ab,ti OR responsive*:ab,ti OR ('limit':ab,ti AND 'detection':ab,ti) OR 'minimal 
detectable concentration':ab,ti OR interpretab*:ab,ti OR (small*:ab,ti AND ('real':ab,ti OR 'detectable':ab,ti) AND ('change':ab,ti OR 'difference':ab,ti)) OR 
'meaningful change':ab,ti OR 'minimal important change':ab,ti OR 'minimal important difference':ab,ti OR 'minimally important change':ab,ti OR 'minimally 
important difference':ab,ti OR 'minimal detectable change':ab,ti OR 'minimal detectable difference':ab,ti OR 'minimally detectable change':ab,ti OR 
'minimally detectable difference':ab,ti OR 'minimal real change':ab,ti OR 'minimal real difference':ab,ti OR 'minimally real change':ab,ti OR 'minimally real 
difference':ab,ti OR 'ceiling effect':ab,ti OR 'floor effect':ab,ti OR 'item response model':ab,ti OR 'irt':ab,ti OR 'rasch':ab,ti OR 'differential item 
functioning':ab,ti OR 'dif':ab,ti OR 'computer adaptive testing':ab,ti OR 'item bank':ab,ti OR 'cross-cultural equivalence':ab,ti 
CINAHL 
aphasia OR dysphasia AND stroke 
AND 
TI psychometr* OR TI observer variation OR TI reproducib* OR TI reliab* OR TI unreliab* OR TI valid* OR TI coefficient OR TI homogeneity OR TI 
homogeneous OR TI “internal consistency” OR AB psychometr* OR AB observer variation OR AB reproducib* OR AB reliab* OR AB unreliab* OR AB 
valid* OR AB coefficient OR AB homogeneity OR AB homogeneous OR AB “internal consistency” OR (TI cronbach* OR AB cronbach* AND (TI alpha 
OR AB alpha OR TI alphas OR AB alphas)) OR (TI item OR AB item AND (TI correlation* OR AB correlation* OR TI selection* OR AB selection* OR TI 
reduction* OR AB reduction*)) OR TI agreement OR TI precision OR TI imprecision OR TI “precise values” OR TI test-retest OR AB agreement OR AB 
precision OR AB imprecision OR AB “precise values” OR AB test-retest OR (TI test OR AB test AND TI retest OR AB retest) OR (TI reliab* OR AB 
reliab* AND (TI test OR AB test OR TI retest or AB retest)) OR TI stability OR TI interrater OR TI interrater OR TI intrarater OR TI intra-rater OR TI 
intertester OR TI inter-tester OR TI intratester OR TI intra-tester OR TI interobserver OR TI inter-observer OR TI intraobserver OR TI intra-observer OR TI 
intertechnician OR TI inter-technician OR TI intratechnician OR TI intra-technician OR TI interexaminer OR TI inter-examiner OR TI intraexaminer OR TI 
intra-examiner OR TI interassay OR TI inter-assay OR TI intraassay OR TI intra-assay OR TI interindividual OR TI inter-individual OR TI intraindividual 
OR TI intra-individual OR TI interparticipant OR TI inter-participant OR TI intraparticipant OR TI intra-participant OR TI kappa OR TI kappa’s OR TI 
kappas OR TI repeatab* OR AB stability OR AB interrater OR AB inter-rater OR AB intrarater OR AB intra-rater OR AB intertester OR AB inter-tester OR 
AB intratester OR AB intra-tester OR AB interobserver OR AB inter-observer OR AB intraobserver OR AB intra-observer OR AB intertechnician OR AB 
inter-technician OR AB intratechnician OR AB intra-technician OR AB interexaminer OR AB inter-examiner OR AB intraexaminer OR AB intra-examiner 
OR AB interassay OR AB inter-assay OR AB intraassay OR AB intra-assay OR AB interindividual OR AB inter-individual OR AB intraindividual OR AB 
intra-individual OR AB interparticipant OR AB inter-participant OR AB intraparticipant OR AB intra-participant OR AB kappa OR AB kappa’s OR AB 
kappas OR AB repeatab* OR ((TI replicab* OR AB replicab* OR TI repeated OR AB repeated) AND (TI measure OR AB measure OR TI measures OR AB 
measures OR TI findings OR AB findings OR TI result OR AB result OR TI results OR AB results OR TI test OR AB test OR TI tests OR AB tests)) OR TI 
generaliza* OR TI generalisa* OR TI concordance OR AB generaliza* OR AB generalisa* OR AB concordance OR (TI intraclass OR AB intraclass AND TI 
correlation* or AB correlation*) OR TI discriminative OR TI “known group” OR TI factor analysis OR TI factor analyses OR TI dimension* OR TI 
subscale* OR AB discriminative OR AB “known group” OR AB factor analysis OR AB factor analyses OR AB dimension* OR AB subscale* OR (TI 
multitrait OR AB multitrait AND TI scaling OR AB scaling AND (TI analysis OR AB analysis OR TI analyses OR AB analyses)) OR TI item discriminant 
OR TI interscale correlation* OR TI error OR TI errors OR TI “individual variability” OR AB item discriminant OR AB interscale correlation* OR AB error 
OR AB errors OR AB “individual variability” OR (TI variability OR AB variability AND (TI analysis OR AB analysis OR TI values OR AB values)) OR (TI 
uncertainty OR AB uncertainty AND (TI measurement OR AB measurement OR TI measuring OR AB measuring)) OR TI “standard error of measurement” 
OR TI sensitiv* OR TI responsive* OR AB “standard error of measurement” OR AB sensitiv* OR AB responsive* OR ((TI minimal OR TI minimally OR TI 
clinical OR TI clinically OR AB minimal OR AB minimally OR AB clinical OR AB clinically) AND (TI important OR TI significant OR TI detectable OR 
AB important OR AB significant OR AB detectable) AND (TI change OR AB change OR TI difference OR AB difference)) OR (TI small* OR AB small* 
AND (TI real OR AB real OR TI detectable OR AB detectable) AND (TI change OR AB change OR TI difference OR AB difference)) OR TI meaningful 
change OR TI “ceiling effect” OR TI “floor effect” OR TI “Item response model” OR TI IRT OR TI Rasch OR TI “Differential item functioning” OR TI DIF 
OR TI “computer adaptive testing” OR TI “item bank” OR TI “cross-cultural equivalence” OR TI outcome assessment OR AB meaningful change OR AB 
“ceiling effect” OR AB “floor effect” OR AB “Item response model” OR AB IRT OR AB Rasch OR AB “Differential item functioning” OR AB DIF OR AB 
“computer ad 
 
  
Supplementary Table 1 
ROMA consensus meeting facilitators 
Sarah J. Wallace PhD BSpPath(Hons) 
GradCert Gerontology CPSP 
Certified Practising Speech Pathologist 
and Teaching and Research Academic, 
School of Health and Rehabilitation 
Sciences, The University of Queensland. 
Expertise: post-stroke aphasia 
rehabilitation, core outcome set 
development, stakeholder perspectives, 
consensus processes, ICF. 
Linda Worrall PhD BSpThy FSPA 
Speech Pathologist, Teaching and 
Research Academic, School of Health 
and Rehabilitation Sciences, The 
University of Queensland, Australia.  
Expertise: post-stroke aphasia 
rehabilitation, ICF, aphasia trial design 
and conduct, consumer perspective, 
aphasia rehabilitation guideline 
development.  
Guylaine Le Dorze Ph.D MSc (A) 
Teaching and Research Academic, 
Speech-Language Pathologist, School of 
Speech-Language Pathology and 
Audiology, Faculty of Medicine, 
Université de Montréal. 
Expertise: post-stroke aphasia 
rehabilitation, participation, single-
subject designs, qualitative methods. 
Tanya Rose PhD BSpPath(Hons) 
GradCert Higher Ed CPSP 
Certified Practising Speech Pathologist 
and Teaching and Research Academic, 
School of Health and Rehabilitation 
Sciences, The University of Queensland. 
Expertise: Post-stroke aphasia 
rehabilitation, paediatric and adult 
language, accessible health information, 
mixed-methods research.  
 
ROMA consensus panel 
Edna Babbitt PhD CCC-SLP BC-
ANCDS 
Research Speech-Language Pathologist 
Assistant Research Professor, 
Department of Physical Medicine and 
Rehabilitation, Feinberg School of 
Medicine, Northwestern University, 
Chicago, USA & Shirley Ryan 
AbilityLab, Chicago, USA. 
Expertise: Post-stroke aphasia 
assessment and rehabilitation. 
Arpita Bose PhD MSc (Speech and 
Hearing) BSc (Audiology and Speech 
Rehabilitation). Speech and Language 
Therapist, Teaching and Research 
Academic, School of Psychology and 
Clinical Language Sciences, University 
of Reading, Reading, UK.  
Expertise: Post-stroke aphasia 
assessment and rehabilitation, 
bilingualism, single subject 
experimental designs, quality of life 
issues in aphasia, SLT training in 
decision-making in aphasia. 
Marian Brady PhD BSc  
Speech and language therapist, Director 
Stroke Rehabilitation Research, 
NMAHP Research Unit, Glasgow 
Caledonian University, Glasgow, 
Scotland. 
Expertise: Stroke rehabilitation, design, 
development and evaluation of complex 
multidisciplinary interventions, survey, 
mixed methods, systematic review, meta-
analyses and the use of randomised 
controlled trial archives. 
Caterina Breitenstein PhD academic 
degrees in Clinical Psychology and 
Cognitive Neuroscience. 
Teaching and Research Academic, Dept. 
of Neurology, University of Muenster, 
Germany. 
Expertise: Development and national 
adaptations of communication outcome 
measures, clinical trials methodology, 
intervention studies in post-stroke 
aphasia rehabilitation. 
Leora R. Cherney PhD CCC-SLP 
BC-ANCDS. Research Scientist and 
Speech and Language Pathologist. 
Shirley Ryan AbilityLab (formerly the 
Rehabilitation Institute of Chicago) and 
Northwestern University, Chicago, IL 
USA.  Expertise: Post-stroke aphasia 
 David Copland PhD BSpPath (Hons) 
Speech Pathologist, Principal Research 
Fellow, School of Health & 
Rehabilitation Sciences and Centre for 
Clinical Research, The University of 
Queensland, Brisbane, Australia. 
Madeline Cruice PhD BSpPath 
(Hons) 
Registered Speech and Language 
Therapist, Reader, Teaching and 
Research Academic, School of Health 
Sciences, City University of London, 
London, UK. 
Pam Enderby PhD MBE DSc (Hons) 
MSc FRCSLT 
Speech and Language Therapist, 
Professor Emeritus of Community 
Rehabilitation, University of Sheffield, 
Sheffield. UK. 
assessment and rehabilitation, 
development and evaluation of novel 
aphasia treatments, single subject and 
RCT design, systematic reviews. 
Expertise: Post-stroke aphasia 
assessment and rehabilitation, aphasia 
trial design and conduct, neuroimaging 
in aphasia. 
Expertise: Post-stroke aphasia 
rehabilitation, therapeutic process and 
evaluation, quality of life evaluation in 
research and clinical practice, 
behaviour change. 
Expertise: Aphasia 
management, Clinical Evaluation of 
Interventions, RCTs, Psychometric 
Properties of Outcome Measures. 
Deborah Hersh PhD MSc BSc(Hons) 
GradCert Higher Ed FSPA. 
Speech Pathologist, Teaching and 
Research Academic, School of Medical 
and Health Sciences, Edith Cowan 
University, Perth, Australia. 
Expertise: Post-stroke aphasia 
rehabilitation, consumer perspective, 
aphasia rehabilitation guideline 
development. 
Katerina Hilari PhD MRCSLT 
MHPC 
Psychologist, Registered Speech and 
Language Therapist, Teaching and 
Research Academic, School of Health 
Sciences, City, University of London, 
UK. 
Expertise: Outcome measurement 
development, validation and cultural 
adaptation, post-stroke aphasia 
rehabilitation, feasibility RCTs, clinical 
guideline development. 
 
Tami Howe PhD MHSc BEd SLP(C) 
Speech Pathologist and Teaching and 
Research Academic, School of 
Audiology and Speech Sciences, 
University of British Columbia, 
Vancouver, Canada. 
Expertise: Aphasia rehabilitation, 
ICF, accessibility, goal setting, social 
participation, impact of aphasia on 
family members. 
Helen Kelly PhD MRCSLT 
Registered Speech and Language 
Therapist, Teaching and Research 
Academic, Department of Speech and 
Hearing Sciences, University College 
Cork, Cork, Ireland. 
Expertise: Post-stroke aphasia 
assessment and management, single 
subject and RCT feasibility aphasia trial 
design and conduct, consumer 
perspective. 
Swathi Kiran PhD CCC-SLP 
Speech Language pathologist, Teaching 
and Research Academic. Professor, 
Associate Dean for Research 
Sargent College of Health and 
Rehabilitation Sciences, 
Boston University, Boston, MA, USA. 
Expertise: Aphasia rehabilitation, 
neuroimaging, bilingualism, single 
subject experimental design. 
Ann-Charlotte Laska MD 
A/Professor 
Department of Clinical Science 
Karolinska Institutet 
Danderyd Hospital, Sweden 
Expertise: Post-stroke aphasia, study 
design and conduct, RCT. 
 
Jane Marshall PhD Post Grad 
Diploma in Clinical Communication 
Studies BA FRCSLT 
Registered Speech and Language 
Therapist, Teaching and Research 
Academic, School of Health Sciences, 
City, University of London, UK. 
Expertise: Post-stroke aphasia 
rehabilitation, the development and 
evaluation of novel treatments. 
 
Marjorie Nicholas PhD CCC-SLP 
Professor and Interim Chair 
Dept. of Communication Sciences and 
Disorders, MGH Institute of Health 
Professions, Boston, MA, USA. 
Expertise: Aphasia rehabilitation, 
nonverbal cognition in aphasia, Life 
Participation Approach to Aphasia and 
community aphasia program design, 
ICAP design. 
Janet Patterson PhD CCC-SLP 
ASHA Fellow 
Chief, Audiology & Speech-Language 
Pathology Service, VA Northern 
California Health Care System 
Practicing Speech-Language 
Pathologist, Teaching and Research 
Academic.  
Expertise: Post-stroke aphasia 
Gill Pearl MPhil Dip Hum Commun. 
Certified practicing speech and language 
therapist in role as Chief Executive 
Officer of Speakeasy - specialist aphasia 
centre, UK.  
Expertise: Development and evaluation 
of novel approaches to providing long 
term aphasia support and therapy, 
facilitator of consumer involvement in 
Elizabeth Rochon PhD MSc (A) Reg 
CASLPO SLP(c) 
Speech Pathologist, Teaching and 
Research Academic, Department of 
Speech-Language Pathology and 
Rehabilitation Sciences Institute, 
University of Toronto, Canada. 
Expertise: Post-stroke aphasia 
assessment and rehabilitation, 
development of aphasia treatment 
Miranda Rose PhD BSpPath FSPA 
Speech pathologist, Teaching and 
Research Academic, School of Allied 
Health, La Trobe University, Victoria, 
Australia.  
Expertise: Post-stroke aphasia 
rehabilitation, aphasia trial design and 
conduct, single subject designs, 
consumer perspective, aphasia 
rehabilitation guideline development. 
rehabilitation, systematic reviews of 
literature, single subject designs. 
 
research, feasibility studies, case series 
studies, RCT design and conduct. 
studies, feasibility studies, single subject 
and RCT design, systematic reviews. 
Karen Sage PhD Dip DisHumComm 
BA (Hons) HCPC  
Registered Speech and Language 
Therapist, MRCSLT; Teaching and 
Research Academic, Department of 
Allied Health Professions, Sheffield 
Hallam University, Sheffield, UK.  
Expertise: Aphasia assessment and 
management, stroke rehabilitation, 
single case, case series, mixed methods. 
Steven L. Small PhD MD 
Professor of Neurology, University of 
California, Irvine 
Expertise: Neurobiology of Language, 
Cognitive Neurology. 
Janet Webster PhD MRCSLT 
Registered Speech and Language 
Therapist, Teaching and Research 
Academic, Newcastle University, UK 
Expertise: Post-stroke aphasia 
assessment and management, single 
subject design. 
 
 
Supplementary Table 2 
OMIs (n=50) identified in scoping review and retained following application of the 
consensus-based criteria 
Construct Outcome measurement instrument 
La
ng
ua
ge
 
• The Comprehensive Aphasia Test (CAT) (1) 
• The Western Aphasia Battery Revised (WAB-R) (AQ+LQ) (2) 
• Therapy Outcome Measures (TOM) (3-5) 
• The Aphasia Checklist (ACL) (6) 
• Aachen Aphasia Test (AAT) (7) 
• Aphasia Language Assessment Test (ALA) (8) 
• The Thai Aphasia Language Performance Scales (ALPS) (9) 
• Bilingual Aphasia Test (BAT) (10) 
• The Boston Diagnostic Aphasia Examination  (BDAE) (11) 
• Ege Aphasia Test (12) 
• Kentucky Aphasia Test (KAT) (13) 
• Montreal-Toulouse Language Assessment Battery (MTL) (14) 
• The Norsk Grunntest for Afasi  (NGTA) (15) 
Em
ot
io
na
l w
el
l-b
ei
ng
 
• Communication Confidence Rating Scale for Aphasia (CCRSA) (16) 
• Hospital Anxiety and Depression Scale (HADS) (17) 
• Montgomery-Asberg Depression Rating Scale (MADRS) (18) 
• Geriatric Depression Scale (GDS) 15 item / 30 item (19, 20) 
• Warwick and Edinburgh mental well-being scale (21) 
• Geriatric anxiety scale (22) 
• Stroke and Aphasia (SAD) Scale (23) 
• Signs of Depression Scale (SODS) (24) 
• Stroke Aphasic Depression Questionnaire (SADQ) (25) 
• Visual Analogue Self-Esteem Scale (VASES) (26) 
• Centre for Epidemiology Depression Scale –Revised (27) 
• General Health Questionnaire (GHQ) 12 item (28) 
• Therapy Outcome Measures (TOM) (29-31) 
• Patient Health Questionnaire 2 item / 9 item  (32, 33) 
• Visual Analogue Mood Scale (VAMS) (34) 
Co
m
m
un
ic
at
io
n 
• Aphasia Communication Outcome Measure (ACOM) (35)  
• American Speech-Language and Hearing Association Functional Assessment 
of Communication Skills for Adults (ASHA-FACS) (36) 
• Amsterdam-Nijmegen Everyday Language Test (ANELT) (37) 
• The Communication Activity Log (CAL) (38) 
• The Communication Outcome After Stroke (COAST) (39) 
• The Communicative Activities Checklist (COMACT) (40) 
• The Social Activities Checklist (SOCACT) (40) 
• The Communication Disability Profile (CDP) (41) 
• The Communication Effectiveness Index (CETI) (42) 
• Community Integration Questionnaire (CIQ-R) (43) 
• Communication Activities of Daily Living (CADL) (44) 
• The Functional Outcome Questionnaire for Aphasia (FOQ-A) (45) 
• Measure of participation in conversation (MPC) (46) 
• The Scenario Test (47) 
• The Speech Questionnaire (48) 
• Therapy Outcome Measures (TOM) (29-31) 
• The Communication Participation Item Bank (49) 
Q
ua
lit
y 
of
 L
ife
 
• Aachen Life Quality Inventory (ALQI) (50) 
• Burden of Stroke Scale (BOSS) (51) 
• The Newcastle Stroke-Specific Quality of Life Measure (NEWSQOL) (52) 
• Short Form 36 Health Survey (SF-36)  (53) 
• Stroke and Aphasia Quality of Life Scale (SAQOL-39) (54, 55) 
 
 
Supplementary Table 3 
Description of recommended outcome measurement instruments 
 Outcome 
instrument and 
abbreviation 
Development / 
alternate versions 
Aims/instrument 
description 
Number 
of items 
Duration Scoring system Training Cost*/ 
availability 
Language 
translations 
Western 
Aphasia 
Battery 
Revised 
(WAB-R) (2) 
Developed by 
Kertesz in 1979 
based on the 
original format of 
the Boston 
Diagnostic 
Aphasia 
Examination (56). 
 
Revisions 
published in 1982 
and 2006 (WAB-
R): 
Supplemental 
tasks, revision of 
15 items and 
testing materials 
(e.g. spiral-bound 
stimulus book 
replacing loose 
stimulus cards), as 
well as revised 
directions and 
scoring guidelines 
for clarity.  
 
The WAB-R also 
includes a bedside 
screening tool 
(Bedside WAB-
R). 
Primary: Assessment 
of linguistic skills in 
aphasia: 
1. Spontaneous speech 
2. Auditory verbal 
comprehension 
3. Repetition 
4. Naming and word 
finding 
5. Reading 
6. Writing 
7. Apraxia 
8. Constructional, 
visuospatial, and 
calculation tasks 
9. Supplemental 
writing and reading 
tasks: reading and 
writing of irregular 
and non-words 
(WAB-R only) 
Secondary: Assessment 
of non-linguistic skills 
in aphasia: 
drawing, block design, 
calculation, and praxis 
1. Additional aims: 
Classification of 8 
aphasia types: 
Global, Broca’s, 
Transcortical motor, 
Wernicke’s, 
>300 • Bedside WAB-
R: 15 min 
(comprises half 
of the items of 
WAB-R Part 1) 
• Part 1: 30-45 
min 
• Part 2: 45-60 
min 
• Aphasia Quotient 
(AQ): a weighted 
average of the 
WAB spoken 
language subtest 
scores.  
• Cortical Quotient 
(CQ): a weighted 
average of both 
the language and 
non-language 
subtest scores. 
• The Language 
Quotient (LQ): 
reflects auditory 
comprehension, 
oral expression, 
reading, and 
writing 
performance. 
Administration: 
“some training” 
required 
according to 
developers. 
Scoring 
procedures 
require training. 
Testing 
materials: 
+++  
 
Available 
from: 
https://ww
w.pearsonc
linical.com  
Cantonese (57)  
Korean (58) 
Bangla (59) 
Tagalog (60)  
Brazilian 
Portuguese (61) 
Japanese (62) 
Hungarian 
French 
Turkish (63) 
Hebrew 
Spanish (64) 
 
 
Transcortical 
sensory, Mixed 
transcortical, 
Conduction, and 
Anomic 
2. Assessment of 
aphasia severity 
3. Used to determine 
the location of the 
lesion 
Stroke and 
Aphasia 
Quality of 
Life Scale 
(SAQOL-39; 
SAQOL-39g) 
(54, 55) 
The SAQOL-
39 is the short 
form of the 
SAQOL (53 
items), which 
is itself an 
adaptation of 
the SS-QOL 
(Stroke-
specific 
Quality of life 
scale). 
The SAQOL-
39 was 
originally 
tested in 
people with 
chronic 
aphasia (the 
measure had 
four domains: 
physical, 
psychosocial 
communicatio
n, energy. 
Interview-administered 
self-report measure, 
SAQOL-39 comprises 
39 questions, in four 
quality of life (QoL) 
domains: 
 
1. Physical (17 items)  
2. Communication (7 
items) 
3. Psychosocial (11 
items) 
4. Energy (4 items) 
 
SAQOL 39g comprises 
the same 39 questions, 
in three quality of life 
(QoL) domains: 
 
1. Physical (16 items)  
2. Communication (7 
items) 
3. Psychosocial (16 
items) 
 
Timeframe for all 
questions is the past 
week 
 
39 • 15-20 min 
(depending on 
severity of 
aphasia) 
• Twenty-one of 
the items ask the 
respondents how 
much trouble 
they have had 
with activities 
(e.g., getting 
dressed, 
speaking). The 
response format 
for these 
questions is a 5-
point scale that 
varies from 
1=‘couldn’t do it 
at all’ to 5=‘no 
trouble at all’. 
The rest of the 
items (18) ask 
about feelings 
(e.g., ‘did you 
feel irritable?’) 
and other 
activities (e.g., 
‘did you see your 
friends less often 
than you would 
like?’). Their 
response format 
Administration: 
Guidance is 
provided in 
administration 
guidelines. 
Administrators 
need to have 
skills in 
communicating 
with people 
with aphasia 
Scoring 
procedures: no 
training required 
Free. 
 
Available 
from: 
https://blog
s.city.ac.uk
/cityaccess
/saqol-
description
/  
Chilean (68) 
Chinese (69) 
Chinese 
mandarin (70) 
Dutch (71) 
Greek (72, 73)  
Hindi (74)  
Italian (75) (76) 
Japanese (77) 
Kannada (78) 
Korean (79) 
Malayalam (80) 
Persian (81) 
Portuguese (82) 
Spanish (83) 
Turkish (84) 
 
Testing the 
SAQOL-39 in 
generic stroke 
population (n=87) 
resulted in the 
SAQOL-39g, 
which has the 
same items as the 
SAQOL-39 but 
three domains (all 
energy items 
groups with the 
psychosocial 
domain).  
 
There are 
alternative forms 
for proxy 
administration 
(65, 66) and for 
postal and 
telephone 
administration 
(67) 
Multi-modal 
presentation, i.e., 
patients can both read 
and listen to the 
questions. People with 
expressive aphasia can 
point to their responses 
instead of verbally 
responding. 
varies from 
1=‘definitely 
yes’ to 
5=‘definitely 
no’. 
 
Calculation of:  
1. total score: mean 
score of all 39 
items 
2. Domain scores: 
mean score of all 
items relating to 
the respective 
domain 
General 
Health 
Questionnaire 
(GHQ) 12 
Developed in 
1972. Current 
version published 
in 2011) 
 
Alternate 
versions: 
• GHQ-60: 60-
item 
questionnaire 
• GHQ-30: a 
short form 
without items 
relating to 
Primary: Screening 
device for identifying 
minor psychiatric 
disorders in the general 
population and within 
community or non-
psychiatric clinical 
settings such as primary 
care or general medical 
out-patients. 
 
12 questions relating to 
symptoms of various 
psychiatric conditions, 
assesses the respondent's 
12 2 min 
administration time 
(in non-language 
impaired samples) 
4-scale response 
options (exact 
wording depends on 
item): 
1. 'better/healthier 
than normal'  
2. 'same as usual'  
3. 'worse/more than 
usual'  
4. ‘much 
worse/more than 
usual' 
Administration: 
no training 
required. 
 
Scoring 
procedures: no 
training 
required. 
Testing 
materials: 
+ 
 
Available 
from: 
https://ww
w.gl-
assessment
.co.uk 
 
Italian (85) 
Arabic (86) 
Turkish (87) 
Persian (88) 
Portuguese (89) 
Kannada (90) 
Hindi (91) 
Spanish (92) 
 
A number of 
other 
unvalidated 
translations are 
available. The 
MAPI Research 
physical 
illness  
• GHQ-28: a 
28 item 
scaled 
version – 
assesses 
somatic 
symptoms, 
anxiety and 
insomnia, 
social 
dysfunction 
and severe 
depression (7 
items for 
each of the 
four scales) 
current state and asks if 
that differs from his or 
her usual state, and is 
therefore sensitive to 
short-term psychiatric 
disorders. 
4 possible methods of 
scoring. GHQ scoring 
(0-0-1-1) is 
advocated by the test 
author. 
 
GHQ-12 yields only 
an overall total score 
(range: 0 to 12 points 
with standard scoring 
procedure). 
 
Trust distributes 
translated 
versions on 
behalf of GL 
Assessment. 
Contact: 
PROinformation
@mapi-trust.org  
 
* Free, + Up to US$100, ++ Up to US$200, +++ > US$200 
  
Supplementary Table 4 
Properties of recommended outcome measurement instruments 
 
 Western Aphasia Battery – Revised (WAB-R)  Stroke and Aphasia Quality of Life Scale (SAQOL-
39/39g) 
General Health Questionnaire (GHQ-12) 
Objectivity • During assessment: Limited because no 
audio recordings of verbal stimulus 
material available 
• During scoring: Limited for spontaneous 
speech and written output subtests 
• During assessment: Moderate (interaction 
between assessor and patient frequently 
required because of physical stroke symptoms 
(arm paresis) and lack of pictorial task 
instructions (written sentences only) 
• During scoring: High 
• During assessment: High if assessor 
does not interact with patient 
• During scoring: High 
Internal 
consistency 
High: Cronbach’s alpha of total score= 0.91 
(93).  
High: Cronbach’s alpha of total score= 0.93; 
Cronbach’s alpha of subscale scores= 0.74–0.94 
(54). 
 
SAQOL-39g: High: Cronbach’s alpha of total 
score= 0.95; Cronbach’s alpha for subscale scores= 
0.92-0.95 (55) 
High (in general population): Cronbach’s 
alpha of total score= 0.79-0.91 (94-96). 
Cronbach’s alpha of subscale scores= 
0.80-0.92.  
 
Test-retest 
reliability* 
Excellent test-retest reliability: r >0.90 
 
Acute stage post stroke:  
• Korean version; (58); 5-day test–retest 
interval (n=20 people with aphasia; 
Aphasia Quotient: r=0.976; Language 
Quotient: r=0.977; Cortical Quotient: 
r=0.920; Spontaneous Speech: r=0.96; 
Auditory Comprehension: r=0.967; 
Repetition: r=0.952; Naming: r=0.934; 
Reading: r=0.986; Writing: r=0.988; 
Praxis, r=0.908; Construction: r=0.922).  
 
Chronic stage post stroke: 
• 1 year test–retest interval (97), n=22 
patients, r=0.992 
Good to excellent test-retest reliability ICC=0.89-
0.98 
 
• English version; 2 to 14 days; n=17 people 
with aphasia; ICC=0.98 overall, 0.94–0.98 
subscales (54). 
• English generic stroke version (SAQOL-39g); 
7 ± 4 day test–retest interval; n=18 people with 
stroke/ stroke and aphasia; ICC= 0.96 overall; 
ICC= 0.92–0.98 subscales (55) 
 
Other translated versions: 
• Chilean version; ICC=0.95 (67) 
• Chinese  ICC=0.97(69) 
• Chinese mandarin version; ICC=0.98 (70) 
• Dutch  ICC=0.9 (71) 
• Greek ICC=0.96 (73) 
Acceptable to excellent test-retest 
reliability  
 
• General population: ICC=0.79-0.82 
(100) 
 
• Stroke (inc. aphasia) population using 
GHQ-28:  2 month test-retest 
reliability with a sample of 20 
individuals (r=0.90) (101) 
• 6 months to 6.5 test–retest interval (av. 
12-23 months test–retest interval; (93)), 
n=38  patients with chronic aphasia; 
WAB-AQ (r=0.968), WAB-CQ (n=9, 
r=0.895), WAB-LQ subtests: 
Spontaneous Speech – Information 
Content (r=0.947) and Fluency (r=0.941), 
Comprehension (r=0.881), Repetition 
(r=0.970), Naming (r=0.923), Reading 
(n=32; r=0.927) and Writing (n=25; 
r=0.956) and the Construction subtest 
(n=14, r=974). Test-retest reliability was 
adequate for the Praxis subtest (n=18, 
r=0.581). 
• Danish version (98); 3.5 months test–
retest interval; n=19, r=0.96.  
• Cantonese version (99); 12 to 16 months 
test–retest interval; n=16 patients, 
Spontaneous Speech subtest – 
Information, Fluency and total scores 
(r=0.83, 0.94, 0.96 respectively), Naming 
subtest (r=0.91), AQ (r=0.93).  
• Hindi  ICC=0.9 (74) 
• Italian  ICC=0.916 (75) (76) 
• Japanese  ICC=0.97 (77) 
• Kannada  ICC=0.8 (78) 
• Korean  ICC=0.909 (79) 
• Malayalam  ICC=0.91 (80) 
• Persian ICC=0.93 (81) 
• Portuguese  ICC=0.927 (82) 
• Spanish  ICC=0.949 (83) 
• Turkish ICC=0.97 (84) 
 
Responsiveness Sub-/acute phase (up to 1 month post-onset):  
• WAB-LQ: n=50 adults with aphasia 
secondary to acute stroke, who received 
treatment (n=42) or no treatment (n=8). 
Participants assessed at baseline (2-4 
weeks post-onset of aphasia), 3 months, 
and at least 6 months post-baseline. 
Significant main effect for time (F=43.33, 
df=2.96, p<0.0001), significant 
differences in the mean scores for the 
three tests (p<0.01). (102) 
• Very Early Rehabilitation of Speech 
(VERSE) trial; n=20 participants with 
mild-severe aphasia receiving 
intervention (4-5 h/wk for 5 wks) 
achieved 18% greater recovery on the 
Acute to post-acute phase (up to 6 months post-
onset):  
• Generic stroke sample, n=87; people admitted 
to hospital with a first stroke were assessed two 
weeks, three months and six months post 
stroke. Moderate changes (d = 0.35—0.49; 
standardized response mean (SRM) = 0.29—
0.53) from two weeks to six months support 
responsiveness. (55) 
 
Post-acute to chronic (3 months to 1 year) 
• Cohort study of stroke sample with and without 
aphasia, n=78. Effect size r=0.22. MID 
estimated 0.21. (107) 
 
Chronic phase (at least 6 months post-onset):  
Acute to post-acute phase (up to 6 months 
post-onset):  
• Impact of stroke with and without 
aphasia across the first six months, 
n=87 people with stroke or stroke and 
aphasia; psychological distress 
significantly reduced with time on 
GHQ-12 [F (2,140) = 7.1, p=0.001] 
(109) 
 
Chronic phase (at least 6 months post-
onset):  
• Effects of singing in a community 
choir on mood; n=13 people with 
aphasia; 2.8 point reduction in mean 
GHQ-12 score was seen by week 12, 
WAB-AQ compared to the usual care 
group (11 min/week for 3 wks) (103). 
 
Post-acute phase (2-6 months post-onset):  
• See (102) above 
• Prospective longitudinal study with n=75 
participants with aphasia post stroke, 
assessments at 4, 8, 12 and 24 weeks 
post-stroke, significant improvement in 
WAB-AQ across first year post-stroke 
(104) 
 
Chronic phase (at least 6 months post-onset):  
• n=10 participants with chronic aphasia. 
Combination of d-amphetamine, TMS, 
and SLT superior to control intervention 
of placebo with TMS and SLT; Change in 
AQ (from 36.13[18.23] to 38.60[19.33], P 
= 0.04) and LQ (from 32.41[14.93] to 
35.03[15.10], P = 0.02) showed a 
statistically significant increase in the 
active experiment. Comparison of 
proportional changes of AQ and LQ in 
the active experiment with AQ and LQ in 
the placebo experiment showed a 
significant difference (AQ, P = 0.02; LQ, 
P = 0.008)  (105) 
 
Mixed stages 
• n= 50 participants with aphasia (49 
secondary to subacute or chronic stroke).  
Participants’ mean scores improved 
significantly from pre- to post-treatment 
on all WAB subtests, with absolute 
percentages ranging from 6.5% to 13% 
improvement (p<0.01 to p<0.0001) (106). 
• Intensive speech and language therapy 
compared to a waiting list control condition; 
n=156; Verbal communication was 
significantly improved from baseline to post- 
treatment (mean difference 2·61 points [SD 
4·94]; 95% CI 1·49 to 3·72), but  
not from baseline to after treatment deferral (–
0·03 points [4·04]; –0·94 to 0·88; between-
group difference Cohen’s d=0·58; p=0·0004). 
F-value for the main comparison is 12.97 
(df1=1, df2=153), p= 0.0004  (108) 
suggesting a possible reduction in 
adverse mood symptoms that was 
sustained to week 20. (110) 
• Effects of solution-focused brief 
therapy, n=5 people with aphasia, On 
GHQ-12 the mean (SD) score before 
therapy was 4.80 (4.60) [median 
(IQR) = 6.00 (0–9.00)]. This was 
reduced after therapy to a mean (SD) 
score of 2.00 (2.55) 
[median (IQR) = 1.00 (0–4.50)]. The 
effect size was large: Cohen’s d = 
0.79. (111) 
 
Caregivers of people with aphasia:   
• Impact of a psychoeducation program 
on caregivers' burden and stress, n 
=31 caregivers of people with post 
stroke aphasia. Caregivers in the 
immediate treatment group had 
significant reductions in GHQ-12 
measured stress (GHQ mean (SD) 
at baseline =6.26 (5.67), GHQ post 
treatment 3.21 (SD 4.20), =/0.006). 
(112) 
Convergent 
validity 
• Convergent validity in sample of n=15 
people with aphasia (93). Comparison 
• SAQOL-39: Good convergent validity (r=0.55 
to 0.67)(54). Adequate correlation between 
Convergent validity in post-stroke aphasia 
sample:  
with corresponding subtests of the 
Neurosensory Center Comprehensive 
Examination for Aphasia (NCCEA), 
using Pearson correlation coefficients 
o Excellent correlation between: 
WAB Spontaneous Speech and 
NCCEA Description of Use and 
Sentence Construction (r= 
0.817); WAB Comprehension 
and NCCEA Identification by 
Name and Identification by 
Sentence (r= 0.915); WAB 
Repetition and NCCEA Sentence 
Repetition (r= 0.880); WAB 
Naming and NCCEA Visual 
Naming and Word Fluency (r= 
0.904); WAB Reading and 
NCCEA Reading subtests 
(r=0.919); WAB Writing and 
NCCEA Writing subtests 
(r=0.905); and WAB and 
NCCEA total scores (r=0.973).  
o Excellent correlation between 
the WAB-CQ (minus the Praxis 
and Construction subtests) and a 
comparable NCCEA score 
(minus the Tactile Naming-
Right/Left, Articulation, Digit 
Repetition-Forward/Backward 
subtests) (r=0.964). 
• Sample of n=45 people with aphasia. 
Excellent correlation between the WAB 
and the Czech version of the Mississippi 
Aphasia Screening Test (MASTcz) (r= 
0.933) (113) 
GHQ-12 and the SAQOL-39 mean (0.53, 
p<0.01). The physical, communication, and 
energy subscales show good convergent 
validity (r=0.39 to 0.67, r=0.55, r=0.32, 
respectively). The psychosocial subdomain 
shows adequate convergent (r=0.28 to 0.62) 
validity with only 1 correlation lower than 
predicted (r=0.28 with the SSS). Good 
correlations with Frenchay Activities Index 
(FAI) and ASHA Functional Assessment of 
Communication Skills (ASHA-FACS). 
• SAQOL-39g: Good/excellent convergent 
validity for overall scale (r=0.36–0.70); and 
subdomains (r=0.47–0.78) (55), evidenced by 
moderate to high correlations with measures of 
stroke severity (NIHSS), activities of daily 
living (Barthel Index), extended activities of 
daily living (Frenchay Activities Index), 
emotional distress (GHQ-12) and language 
(Frenchay Aphasia Screening Test). 
• Good correlations with SAQOL 
39/SAQOL-39 (English, Greek, and 
Turkish versions).  
• The GHQ-12 demonstrated good 
convergent validity in a sample of 83 
individuals with chronic stroke and 
aphasia, by comparison with the 
SAQOL-39. The study yielded an 
adequate correlation between the 
GHQ-12 and the SAQOL-39 mean 
(0.53, p<0.01). Correlations between 
the GHQ-12 and SAQOL-39 subtests 
were adequate (physical r=0.39, 
energy r=0.32, p<0.01) to excellent 
(psychosocial r=0.62, p<0.01). (54) 
Discriminant 
validity 
• Sample of n=140 people with aphasia. 
Comparison of WAB with Raven’s 
SAQOL-39: Discriminant validity (r = 0.02-0.27) 
(54) 
 
Excellent discriminant validity in Swedish 
population (n=556 patient cases surveyed 
in specialized psychiatric care outpatient 
age and n=556 sex-matched controls). 
Coloured Progressive Matrices scores 
Adequate correlation (r=0.547). 
• Sample of n=66 people with chronic 
aphasia. Discriminant validity of the 
WAB Aphasia Quotient (WAB-AQ) by 
comparison with the Scandinavian Stroke 
Scale (SSS), Barthel Index (BI) and 
Frenchay Activities Index (FAI). 
Excellent correlation between the WAB-
AQ and the SSS (r=0.64), 
adequate correlations between the WAB-
AQ and the BI (r=0.44) and the FAI 
(r=0.50).  
SAQOL-39g:  Good/excellent discriminant validity 
for overall scale and subdomains, evidenced by low 
to moderate correlations with external measures (r 
= 0.03-0.40). (55) 
Individuals using specialized psychiatric 
services and healthy controls (Likert index 
AUC=0.86, GHQ index 
AUC=0.83), and between individuals with 
current disorder from healthy controls 
(Likert index AUC=0.90, GHQ index 
AUC=0.88). (114). 
* Test-retest reliability: 1=perfect reliability; ≥ 0.9=excellent reliability; ≥ 0.8 < 0.9=good reliability; ≥ 0.7 < 0.8=acceptable reliability; ≥ 0.6 < 0.7=questionable reliability; 
≥ 0.5 < 0.6=poor reliability; < 0.5=unacceptable reliability; 0=no reliability. 
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